Open AccessCandidate‐Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol‐Lowering Response to Simvastatin
Author(s) -
Kitzmiller JP,
Luzum JA,
Dauki A,
Krauss RM,
Medina MW
Publication year - 2017
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12432
Subject(s) - slco1b1 , simvastatin , cyp3a5 , pharmacogenetics , cholesterol , cyp3a4 , statin , biology , medicine , genetics , gene , pharmacology , endocrinology , genotype , cytochrome p450 , metabolism
Cholesterol‐lowering response to 40 mg simvastatin daily for 6 weeks was examined for associations with common genetic polymorphisms in key genes affecting simvastatin metabolism ( CYP3A4 and CYP3A5 ) and transport ( SLCO1B1 ). In white people ( n = 608), SLCO1B1 521C was associated with lesser reductions of total and low‐density lipoprotein cholesterol. Associations between SLCO1B1 521C and cholesterol response were not detected in African Americans ( n = 333). Associations between CYP3A4 *22 or CYP3A5 *3 and cholesterol response were not detected in either race, and no significant race‐gene or gene‐gene interactions were detected. As several of the analyses may have been underpowered (especially the analyses in the African American cohort), the findings not suggesting an association should not be considered conclusive and warrant further investigation. The finding regarding SLCO1B1 521C in whites was consistent with several previous reports. SLCO1B1 521C resulted in a diminished cholesterol‐lowering response, but a marginal effect size limits utility for predicting simvastatin response.